Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial (Q48594003)

13 February 2018

title

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial (English)

1 reference

13 February 2018

main subject

phase II clinical trial

0 references

0 references

1 reference

9

Mario Sznol

1 reference

13 February 2018

7

Jedd D Wolchok

1 reference

13 February 2018

F Stephen Hodi

15

object named as

F Stephen Hodi

1 reference

13 February 2018

author name string

Kim Margolin

1

1 reference

13 February 2018

Marc S Ernstoff

2

1 reference

13 February 2018

Omid Hamid

3

1 reference

13 February 2018

Donald Lawrence

4

1 reference

13 February 2018

David McDermott

5

1 reference

13 February 2018

Igor Puzanov

6

1 reference

13 February 2018

Joseph I Clark

8

1 reference

13 February 2018

Theodore F Logan

10

1 reference

13 February 2018

Jon Richards

11

1 reference

13 February 2018

Tracy Michener

12

1 reference

13 February 2018

Agnes Balogh

13

1 reference

13 February 2018

Kevin N Heller

14

1 reference

13 February 2018

publication date

27 March 2012

1 reference

13 February 2018

Lancet Oncology Commission

published in

1 reference

13 February 2018

volume

13

1 reference

13 February 2018

issue

5

1 reference

13 February 2018

page(s)

459-465

1 reference

13 February 2018

The treatment of brain metastases in melanoma patients

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970090-6

7 January 2021

Prognostic factors for survival in melanoma patients with brain metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970090-6

7 January 2021

Determinants of outcome in melanoma patients with cerebral metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970090-6

7 January 2021

Stereotactic radiosurgery for brain oligometastases: good for some, better for all?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970090-6

7 January 2021

Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970090-6

7 January 2021

Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970090-6

7 January 2021

Prognostic factors for survival after stereotactic radiosurgery vary with the number of cerebral metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970090-6

7 January 2021

Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970090-6

7 January 2021

Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970090-6

7 January 2021

NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970090-6

7 January 2021

Trafficking of immune cells in the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970090-6

7 January 2021

Brain metastases following interleukin-2 plus interferon-alpha-2a therapy: a follow-up study in 94 stage IV melanoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970090-6

7 January 2021

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970090-6

7 January 2021

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970090-6

7 January 2021

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970090-6

7 January 2021

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970090-6

7 January 2021

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970090-6

7 January 2021

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970090-6

7 January 2021

CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970090-6

7 January 2021

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970090-6

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970090-6

7 January 2021

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970090-6

7 January 2021

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970090-6

7 January 2021

Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970090-6

7 January 2021

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970090-6

7 January 2021

Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970090-6

7 January 2021

Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970090-6

7 January 2021

10.1016/S1470-2045(12)70090-6

Identifiers

DOI

1 reference

13 February 2018

1 reference

13 February 2018